智通财经APP获悉，云顶新耀-B(01952)早盘涨超6%，截至发稿，涨4.85%，报48.65港元，成交额1.38亿港元。
消息面上，4月22日，云顶新耀获得联交所正式批准，将“B”标记从股票代码中移除，这是云顶新耀转向“商业化成熟企业”的重要里程碑，标志着云顶新耀在市值和收入等方面达到了更高标准，商业化能力得到进一步认可。
西部证券指出，耐赋康2025年1月1日正式执行国家医保新价格。预计将在2025年获得中国国家药品监督管理局(NMPA)完全批准。预计耐赋康将被纳入2025年发布的改善全球预后(KDIGO)2025指南，并被纳入中国首个IgA肾病指南。此外，公司25年多个产品即将迎来催化事件。EVER001等待随访数据，商业化前景可期；头孢吡肟-他尼硼巴坦预计2025年递交大陆复杂性尿路感染适应症新药申请上市；伊曲莫德大湾区已上市，中国NDA已受理。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.